Safety and cost-effectiveness of Ganoderma lucidum (Reishi mushroom) compared to Ceratonia siliqua in patients with Fibromyalgia: a double-blind, randomised, pilot trial.
Not Applicable
Completed
- Conditions
- FibromyalgiaMusculoskeletal - Other muscular and skeletal disordersAlternative and Complementary Medicine - Herbal remediesNeurological - Other neurological disorders
- Registration Number
- ACTRN12614001201662
- Lead Sponsor
- Francesco Pazzi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
1. Be diagnosed with fibromyalgia;
2. Be able to communicate effectively with study staff;
3. Be aged more than 18 years;
4. Give written informed consent.
Exclusion Criteria
1. Be pregnant;
2. Change the daily life habits during the six weeks of treatment;
3. Take immunosuppressive;
4. Suffer diabetes;
5. Participating in other studies;
6. Take C vitamin supplementation;
7. Take anticoagulants;
Patients may abandon the trial if some circumstances happen: they withdraw informed consent, the researcher or their general practitioner feel that they should withdraw from the study for reasons of safety and the patient does not comply with the treatment for more than 80% of the dose.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method